DiaSorin S.p.A. (DIA) AI Stock Analysis

• Market Cap: €4.28B
• Dividend Yield: 1.52%
• Average Volume (3M): 277.93K
• Price to Earnings (P/E): 22.0
• Beta (1Y): 0.45
• Revenue Growth: 4.69%
• EPS Growth: 15.79%
• Country: IT
• Employees: 3,249
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.12
• Shares Outstanding: 55,948,257
• 10 Day Avg. Volume: 217,351
• 30 Day Avg. Volume: 277,927
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €93.60
• Price Target Upside: 20.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 65 Neutral
• Price Target: €99.00 ▲(26.92% Upside)

DiaSorin S.p.A. demonstrates strong financial performance with solid profitability and effective cash flow management, which is a significant positive factor. However, technical analysis indicates bearish trends, and the valuation suggests the stock might be overvalued, which are notable risks. The absence of impactful earnings call data or corporate events leaves these strengths and risks as the primary influencers of the overall score.

Positive Factors

Negative Factors

DiaSorin S.p.A. Business Overview & Revenue Model

Company Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

How the Company Makes Money

DiaSorin generates revenue primarily through the sale of its diagnostic products and systems to hospitals, laboratories, and healthcare providers worldwide. The company's revenue model is driven by the recurring nature of diagnostic testing, which leads to ongoing sales of consumables such as test kits and reagents. Key revenue streams include the sale of immunoassays, molecular tests, and the related instrumentation. Additionally, DiaSorin benefits from partnerships with healthcare organizations and research institutions, which can enhance its market reach and product development. The company also invests in R&D to innovate and expand its product offerings, ensuring a steady stream of new products that can contribute to its earnings.

DiaSorin S.p.A. Financial Statement Overview

Summary

DiaSorin S.p.A. is financially sound with strong profitability, effective cash flow generation, and a stable balance sheet. The company has demonstrated resilience in revenue growth and maintains a strategic balance between debt and equity, positioning it well for future growth and stability in the medical diagnostics industry.

Income Statement

DiaSorin S.p.A. exhibits strong profitability with a consistent gross profit margin of approximately 66% and a stable net profit margin around 16%. Revenue growth has shown resilience, recovering from a decline in 2022 to a growth of 3.2% in 2024. EBIT and EBITDA margins also reflect robust operational efficiency, with EBIT at 23% and EBITDA at 31% in 2024.

Balance Sheet

The company's balance sheet shows solid equity with a debt-to-equity ratio of 0.53, indicating prudent leverage. Return on equity has improved to 10.4% in 2024, showcasing effective shareholder value creation. The equity ratio remains healthy at 59.5%, reflecting financial stability and reduced risk exposure.

Cash Flow

DiaSorin S.p.A. demonstrates strong cash flow management, with a free cash flow growth of 34.9% in 2024. The operating cash flow to net income ratio is robust at 1.92, and the free cash flow to net income ratio stands at 1.92, indicating efficient conversion of profits into cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.21B	1.19B	1.15B	1.36B	1.24B	881.30M
Gross Profit	793.93M	781.00M	741.19M	900.61M	824.77M	602.90M
EBITDA	330.50M	399.04M	333.40M	479.71M	504.56M	383.62M
Net Income	194.10M	188.10M	159.85M	240.91M	310.97M	247.87M
Balance Sheet
Total Assets	2.61B	3.30B	3.21B	3.41B	3.23B	1.25B
Cash, Cash Equivalents and Short-Term Investments	0.00	378.92M	378.75M	384.19M	403.02M	339.88M
Total Debt	672.00M	1.01B	1.19B	1.35B	1.40B	34.66M
Total Liabilities	928.00M	1.51B	1.67B	1.89B	1.86B	290.13M
Stockholders Equity	1.68B	1.80B	1.54B	1.52B	1.37B	954.68M
Cash Flow
Free Cash Flow	289.73M	239.07M	266.20M	275.65M	283.29M	229.74M
Operating Cash Flow	354.92M	358.78M	311.66M	389.34M	400.66M	304.56M
Investing Cash Flow	-80.97M	-49.81M	-29.10M	-231.95M	-1.61B	-73.02M
Financing Cash Flow	-221.66M	-259.13M	-235.96M	-333.04M	1.26B	-40.89M

DiaSorin S.p.A. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 78.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Negative. The current price of 78 is below the 20-day moving average (MA) of 83.72, below the 50-day MA of 85.99, and below the 200-day MA of 94.07, indicating a bearish trend. The MACD of -2.06 indicates Positive momentum. The RSI at 29.47 is Positive, neither overbought nor oversold. The STOCH value of 3.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:DIA.

DiaSorin S.p.A. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GPI	79 Outperform	511.56M	4.93	33.74%	4.79%	16.92%	0.00%
PHN	73 Outperform	403.21M	23.67	26.72%	2.40%	13.75%	16.66%
REC	69 Neutral	11.05B	27.10	21.77%	2.37%	11.51%	5.23%
DIA	65 Neutral	€4.28B	22.05	12.16%	1.52%	4.69%	15.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%